683 related articles for article (PubMed ID: 26197437)
1. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine 1-phosphate signaling at the blood-brain barrier.
Prager B; Spampinato SF; Ransohoff RM
Trends Mol Med; 2015 Jun; 21(6):354-63. PubMed ID: 25939882
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling.
Mike EV; Makinde HM; Der E; Stock A; Gulinello M; Gadhvi GT; Winter DR; Cuda CM; Putterman C
Front Immunol; 2018; 9():2189. PubMed ID: 30319641
[TBL] [Abstract][Full Text] [Related]
5. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
[TBL] [Abstract][Full Text] [Related]
6. Second generation S1P pathway modulators: research strategies and clinical developments.
Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
[TBL] [Abstract][Full Text] [Related]
7. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
8. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers.
Cartwright TA; Campos CR; Cannon RE; Miller DS
J Cereb Blood Flow Metab; 2013 Mar; 33(3):381-8. PubMed ID: 23168528
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.
Van Doorn R; Van Horssen J; Verzijl D; Witte M; Ronken E; Van Het Hof B; Lakeman K; Dijkstra CD; Van Der Valk P; Reijerkerk A; Alewijnse AE; Peters SL; De Vries HE
Glia; 2010 Sep; 58(12):1465-76. PubMed ID: 20648639
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
12. Modulating sphingosine 1-phosphate signaling with DOP or FTY720 alleviates vascular and immune defects in mouse sepsis.
Hemdan NY; Weigel C; Reimann CM; Gräler MH
Eur J Immunol; 2016 Dec; 46(12):2767-2777. PubMed ID: 27683081
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Hla T; Brinkmann V
Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
[TBL] [Abstract][Full Text] [Related]
14. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and Optimization of
Gusman DH; Shoemake C
Yale J Biol Med; 2017 Mar; 90(1):15-23. PubMed ID: 28356890
[TBL] [Abstract][Full Text] [Related]
16. Regulation of human cerebro-microvascular endothelial baso-lateral adhesion and barrier function by S1P through dual involvement of S1P1 and S1P2 receptors.
Wiltshire R; Nelson V; Kho DT; Angel CE; O'Carroll SJ; Graham ES
Sci Rep; 2016 Jan; 6():19814. PubMed ID: 26813587
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors.
Delgado A; Martínez-Cartro M
Curr Med Chem; 2016; 23(3):242-64. PubMed ID: 26639095
[TBL] [Abstract][Full Text] [Related]
18. Endothelial Sphingosine-1-Phosphate Receptor 4 Regulates Blood-Brain Barrier Permeability and Promotes a Homeostatic Endothelial Phenotype.
Hansen L; Lohfink N; Vutukuri R; Kestner RI; Trautmann S; Hecht M; Wagner PV; Spitzer D; Khel MI; Macas J; Ferreirós N; Gurke R; Günther S; Pfeilschifter W; Devraj K
J Neurosci; 2022 Mar; 42(10):1908-1929. PubMed ID: 34903569
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod (FTY720-P) Does Not Stabilize the Blood-Brain Barrier under Inflammatory Conditions in an in Vitro Model.
Schuhmann MK; Bittner S; Meuth SG; Kleinschnitz C; Fluri F
Int J Mol Sci; 2015 Dec; 16(12):29454-66. PubMed ID: 26690412
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF promotes migration of human monocytes across the blood brain barrier.
Vogel DY; Kooij G; Heijnen PD; Breur M; Peferoen LA; van der Valk P; de Vries HE; Amor S; Dijkstra CD
Eur J Immunol; 2015 Jun; 45(6):1808-19. PubMed ID: 25756873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
